President Donald Trump announced new pricing deals that will dramatically lower the cost of key diabetes and weight-loss drugs, including Ozempic and Wegovy, marking a major victory in his plan to make medicine affordable again.

The deals were reached through the administration’s “Most Favored Nations” pricing strategy with pharmaceutical giants Eli Lilly & Company and Novo Nordisk. These are the fourth and fifth major companies to sign on in recent months.

When purchased through the upcoming TrumpRx website, set to launch early next year, Novo Nordisk’s drugs Wegovy and Ozempic will drop from around $1,000 a month to just $350. The savings for patients with diabetes and obesity are among the steepest in American history.

Eli Lilly’s popular type 2 diabetes and weight-loss treatments, Zepbound and Orforglipron, will fall from over $1,000 to an average of $346 per month.

“Medicare and Medicaid will finally cover the cost of these weight loss drugs for millions of patients suffering from obesity,” President Trump said during an Oval Office announcement.

The new pricing model also applies to upcoming oral versions of the drugs currently under FDA review. Those pill forms will launch at an introductory rate of $150 per month through TrumpRx, according to the White House.

Trump’s deals mean Medicare prices for all four major drugs will now sit at $245 per month — far below what the previous administration had proposed. Officials said the change could save American taxpayers billions while expanding access to life-saving treatments.

The agreements also extend to several other widely used medicines. Under the new terms, Eli Lilly will offer its migraine drug Emgality at $299 per pen, down from $742, and its diabetes medication Trulicity at $389, slashing almost $600 off the list price.

Novo Nordisk will provide its insulin products, including NovoLog and Tresiba, for just $35 a month. These are some of the deepest insulin discounts ever offered to American patients.

The administration also secured massive domestic investments from the two companies — $10 billion from Eli Lilly and $27 billion from Novo Nordisk — with commitments to expand U.S.-based production. If approved, the new Wegovy pill will be manufactured entirely in the United States.

President Trump framed the deals as part of his promise to fight corporate greed and put American patients first. “These candidates are not just applying for a job — they are applying to guard our values and defend our homeland,” USCIS Director Joseph Edlow said earlier this week about a separate Trump initiative, echoing the same spirit of service and reform driving the administration’s approach.

The move follows similar agreements with Pfizer, AstraZeneca, and EMD Serono. Together, these partnerships are reshaping the pharmaceutical landscape, forcing companies to compete for American consumers rather than dictate prices from abroad.

For many Americans who’ve skipped refills or rationed insulin to make ends meet, the announcement offers hope — and proof that the White House is willing to take on Big Pharma to protect everyday families.

As the TrumpRx program prepares to launch, millions are waiting to see the ripple effect it could have on the entire drug market. For now, one thing is clear: the era of unchecked pharmaceutical prices may finally be ending.